Steven Prestrelski, Chief Scientific Officer at Xeris Biopharma Holdings, Inc. (XERS), sold 11,228 shares at $2.42 ($27K) on 2022-02-22, disclosed to the SEC on 2022-02-24.
Scheduled sale ($27k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| XERS | SELL | 2021-01-12 | $57K | — | Filing → |
| XERS | SELL | 2020-01-14 | $55K | — | Filing → |
| XERS | SELL | 2019-10-16 | $453K | — | Filing → |